Online inquiry

IVTScrip™ mRNA-Human ANKRD13D, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WK17901MR)

This product GTTS-WK17901MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ANKRD13D protein. This product can be used in Multilymphoid progenitor cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Human
RefSeq NM_001347901.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 338692
UniProt ID Q6ZTN6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ANKRD13D, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WK17901MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK18690MR IVTScrip™ mRNA-Human Albumin, (Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Albumin
GTTS-WK28240MR IVTScrip™ mRNA-Human APOPT1, (Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA APOPT1
GTTS-WK16049MR IVTScrip™ mRNA-Human AMER3, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMER3
GTTS-WK12097MR IVTScrip™ mRNA-Human AC133, (Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AC133
GTTS-WK12373MR IVTScrip™ mRNA-Human ABI1, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABI1
GTTS-WK6318MR IVTScrip™ mRNA-Human SOST, (Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SOST
GTTS-WK17624MR IVTScrip™ mRNA-Human ANKRD39, (Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ANKRD39
GTTS-WK27407MR IVTScrip™ mRNA-Human ARHGEF10, (Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ARHGEF10
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW